Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Subscribe To Our Newsletter & Stay Updated
